Abstract

We have used multiple sources to identify a population‐representative cohort of newly diagnosed patients with parkinsonism and Parkinson’s disease in the UK over a 2‐year period. All patients have been invited to participate in a detailed clinical assessment either at home or in an outpatient clinic. These assessments have been used to refine clinical diagnoses of parkinsonism using established criteria, and describe some of the phenotypic variability of Parkinson’s disease at the time of diagnosis. The crude incidence of Parkinson’s disease was 13.6/105yr–1 [confidence interval (CI) 11.8–15.6 and of parkinsonism was 20.9/105yr–1 (CI 18.7–23.3). Age‐standardized to the 1991 European population, the incidence figures become 10.8/105yr–1 (CI 9.4–12.4) for Parkinson’s disease and 16.6/105yr–1 (CI 14.8–18.6) for parkinsonism. Thirty‐six per cent of the Parkinson’s disease patients had evidence of cognitive impairment based on their performance in the Mini‐Mental State Examination, a pattern recognition task, and the Tower of London task. The pattern of cognitive deficits seen among these patients using these and further cognitive tasks suggests that sub‐groups of patients based on cognitive ability might be identifiable even in the early stages of disease, which may reflect regional differences in the underlying neuropathological processes.

Parkinson’s disease is a common, chronic neurodegenerative disorder characterized by a combination of motor problems including tremor, rigidity and bradykinesia as well as cognitive, autonomic and affective abnormalities. It is defined pathologically by the presence of α‐synuclein‐positive Lewy bodies in the substantia nigra, and biochemically by the loss of dopamine in the nigrostriatal tract.

Parkinson’s disease, however, cannot be diagnosed with certainty during life. An individual patient with extrapyramidal signs represents a diagnostic challenge because of the heterogeneity of clinical phenotypes that will ultimately meet pathological criteria for Parkinson’s disease, if and when they come to post‐mortem. Indeed, the atypical forms of the disease that are being identified by functional imaging, and the phenotypic overlap between patients with genetic forms of the disease and the larger population of Parkinson’s disease patients in general, makes case definition for Parkinson’s disease even more problematic (Foltynie et al., 2002). In order to try and standardize the diagnosis of Parkinson’s disease, the UK PDS Brain Bank established a set of clinical criteria for diagnosing the condition, which have recently been shown to usefully predict the pathological diagnosis of Parkinson’s disease in the hands of neurology specialists in movement disorders (Hughes et al., 2002). By applying these criteria, some of the ambiguities of diagnosis can be avoided.

Further difficulties in comparing published Parkinson’s disease frequency figures from one study to the next are also due to differing methods of case ascertainment, varying inclusion and exclusion criteria and lack of follow‐up or histology to confirm diagnoses. Although prevalence studies are easier and quicker to perform, it is more difficult to usefully compare prevalence figures from one study to the next, due to international differences in survival. Incidence studies are more useful, although crude rates of disease are less comparable due to the variation in age structure between populations studied and therefore age‐standardized or age‐specific rates are of much greater use. In general, studies using comparable methods have found an age‐standardized incidence of approximately 8–19 per 100 000 population per year (Twelves et al., 2003). Such estimates are important not only in accurately describing the true incidence of Parkinson’s disease but also in planning for appropriate health service provisions and enabling international comparisons of disease frequency for epidemiological research.

Parkinson’s disease has an insidious onset and therefore generally has a subclinical period prior to any symptoms being noticed by the patient (Horstink and Morrish, 1999). The initial symptoms may be mild and progress over some months or years before prompting the patient to visit their doctor. Questioning patients about the date of onset of their symptoms may therefore be inaccurate, and is only a proxy marker for when the underlying neuropathology may have begun, although several incidence studies have adopted such an approach (Brewis et al., 1966; Dupont, 1977; Wender et al., 1989; Granieri et al., 1991; Mayeux et al., 1995; Sutcliffe and Meara, 1995; Fall et al., 1996; Bower et al., 1999). An alternative is to use the date that the diagnosis of Parkinson’s disease is first suspected or diagnosed (Kurland, 1958; Jenkins, 1966; Hofman et al., 1989; Wang et al., 1991; Morens et al., 1996; MacDonald et al., 2000; Chen et al., 2001; Morioka et al., 2002).

In order to accurately predict the incidence of Parkinson’s disease, a number of other issues should be addressed as recommended in a recent review (Twelves et al., 2003). These include the requirements that studies should (i) have an appropriate population base (between 250 000 and 500 000); (ii) be prospective; (iii) use multiple sources of case ascertainment; (iv) incorporate as many as possible of the cases being seen and assessed by a movement disorders expert; (v) use the date of diagnosis as the most practical definition of incidence if prospective methodology is used; (vi) apply broad criteria to ascertain cases followed by more stringent criteria at assessment; (vii) follow up patients where possible; and (viii) report incidence rates by standard age strata.

An increased prevalence of dementia among Parkinson’s disease patients has long been recognized and has previously been quantified in the community by following up population‐based cohorts of the disease (Marttila and Rinne, 1976; Mayeux et al., 1992; Aarsland et al., 1996; Hobson and Meara, 1999). However, less obvious cognitive deficits are also seen among non‐demented Parkinson’s disease patients. Isolated frontal lobe impairments have been described among clinical series of patients (Lees and Smith, 1983; Taylor et al., 1986; Owen et al., 1992; Dubois and Pillon, 1997), although the frequency of these and other patterns of cognitive deficits among a community‐based cohort of patients has only been reported among prevalent patients with longstanding disease (Janvin et al., 2003). There is growing evidence that subtle frontal lobe deficits may be of prognostic value in identifying Parkinson’s disease patients at risk of dementia (Woods and Troster, 2003).

In this study we present frequency figures for the incidence of Parkinson’s disease and parkinsonism in Cambridgeshire, UK, with a population base of ∼700 000: the Cambridgeshire Parkinson’s Incidence from GP to Neurologist‐ (CamPaIGN) Study. Apart from the larger size of the population base, the study fulfils all of the recommendations listed above. Based on detailed assessments of these patients, we also describe, for the first time, the frequency and pattern of cognitive impairments among a population cohort of incident Parkinson’s disease patients. Although we have performed a range of tests on our patients, we recognize that ideally our motor and cognitive assessments would have been even more detailed. However, the community basis of this study inevitably limits the number of assessments that can be performed with an elderly group of individuals.

Methods

Case definitions

Parkinsonism. We attempted to identify every new case of parkinsonism within Cambridgeshire, including all patients presenting with any extrapyramidal symptoms and signs (tremor, rigidity, bradykinesia, micrographia, loss of dexterity, hypomimia, reduced armswing, or parkinsonian gait). We subsequently sought to confirm and refine the diagnoses following assessment, and investigation as appropriate using accepted clinical criteria. The UK Parkinson’s Disease Brain bank criteria (Gibb and Lees, 1988) were used to diagnose cases of Parkinson’s disease. All assessments were carried out by T.F. with a review of all difficult diagnostic cases by R.A.B. Since increasing numbers of genetic forms of the disease are being discovered with phenotypes and pathology indistinguishable from the sporadic forms of the disease, patients with a family history of Parkinson’s disease were not specifically differentiated from the Parkinson’s disease group. The diagnosis of other parkinsonian syndromes were made using (i) the consensus criteria for the diagnosis of dementia with Lewy bodies (DLB) (McKeith et al., 1996); or the facts that (ii) exposure to neuroleptics at the onset of symptoms lead to a diagnosis of ‘drug‐induced parkinsonism’ or (iii) repeated strokes or stepwise progression of symptoms lead to a diagnosis of ‘vascular parkinsonism’, and (iv) absent or minimal responses to dopaminergic therapies lead to a diagnosis of ‘atypical parkinsonism’. ‘Unspecified parkinsonism’ was applied to those cases not seen and in whom insufficient information was available to precisely classify them. All cases irrespective of the original diagnosis have been recruited to the study and followed up, and cases of significant diagnostic uncertainty have been left without a firm diagnosis at this stage.

Incidence. Cases were identified for a 3‐month run in period (September 1, 2000 to November 31, 2000), during which the study was widely advertised, followed by a 25‐month period of case collection (December 1, 2000 to December 31, 2002), followed by 6 months of post‐collection monitoring (January 1, 2003 to June 30, 2003) to ensure that minimal numbers of cases were missed. Details regarding date of symptom onset and date of diagnosis were both noted. Cases suspected of parkinsonism prior to the onset of the study were excluded on the basis that they were prevalent rather than incident.

Cambridgeshire. The County of Cambridgeshire has been defined by the Office of National Statistics according to Local Authority divisions (Office of National Statistics). People living within the county of Cambridgeshire have free access to health‐care and this region has been used as a population denominator in previous studies of neurological disease (Robertson et al., 1996, 1998). Only individuals resident inside the county of Cambridgeshire on the date of diagnosis were accepted as incident cases. The results of the 2001 population census for the County of Cambridgeshire (Office of National Statistics) were used as our denominator figures.

Case ascertainment

Patients who are diagnosed with Parkinsonism are managed in Cambridgeshire by neurologists, geriatricians and general practitioners (GPs). The neurology service is provided at a regional neurology unit in Cambridge, which includes a clinic specifically devoted to Parkinson’s disease. There are further neurological outpatient facilities provided from District General Hospitals in Peterborough and Huntingdon. At least one consultant neurologist and their staff serve each hospital. Geriatric inpatient and outpatient facilities are also provided at all of these hospitals. Three specialist Parkinson’s disease nurses work with both Parkinson’s disease inpatients and outpatients within the county. Incident cases were detected using five sources within the Cambridgeshire, Huntingdon and Peterborough districts. Written requests for notification of patient details were sought from the following sources at 3‐monthly intervals: (i) all GPs; (ii) all neurologists; (iii) all geriatricians; (iv) all Parkinson’s disease specialist nurses; and (v) hospital discharge coding departments.

Frequent personal visits were made to all individuals among sources ii–v, to increase participation. The study was also advertised through presentations given to local branches of the Parkinson’s Disease Society. To encourage GP participation, patients referred by GPs to the study were also given rapid access to NHS outpatient clinics for consultant opinion and management advice.

Case assessment

All patients seen received the same assessment, comprising a detailed history of their disease, level of education, current and all previous occupations; ethnic origin; family history of neurological disease; full drug history; significant co‐morbidity; and referral source. In addition, a standardized neurological assessment was performed including the Unified Parkinson’s Disease Rating Scale (UPDRS) (Fahn et al., 1987), timed motor tests for both hand‐tapping and walking, and the PDQ 39 (Jenkinson et al., 1997) to assess the patients’ quality of life. A further detailed neurological examination was also performed looking specifically for features of other extrapyramidal diseases (e.g. progressive supranuclear palsy, multiple system atrophy and corticobasal degeneration).

Cognitive features of Parkinson’s disease were assessed using standardized, previously validated tests; the mini mental state examination (MMSE) (Folstein et al., 1975), the National Adult Reading Test (NART) (Nelson and O’Connell, 1978) as a measure of premorbid IQ, a test of verbal fluency for words starting with the letters F, A and S for 1 min each (Benton, 1968), and a test of verbal fluency for animals in a 90‐s period (Goodglass, 1972) (tests sensitive to frontal lobe impairment) (Miller, 1985).

The following subsets from the CANTAB battery (Sahakian et al., 1988; Robbins et al., 1994) were also performed. (i) Pattern recognition memory (PRM). This test is sensitive to impairment of temporal lobe function. (ii) Spatial recognition memory (SRM). This test is subserved by both frontal and temporal lobes (Owen et al., 1995b). (iii) The modified version of the Tower Of London task (TOL). This is a test of planning requiring working memory, at which some patients with Parkinson’s disease have been shown to be impaired even in the early stages (Owen et al., 1992, 1995a; Cools et al., 2002). The modified version of the test involves 20 separate tasks, the first six of these being worked through verbally with the patient to ensure adequate comprehension of the task. No help was given for the last 14 tasks and patients were given 1 point for each task they solved correctly at the first attempt, giving a maximum possible score of 14 points. A Beck depression inventory was also performed on each patient (Richter et al., 1998).

Follow‐up

Consenting patients are part of continued annual follow‐up for repeat assessments and for confirmation of diagnoses. At the first annual follow‐up visit, patients are given information about the Brain Donation Scheme, and invited to declare their intent to participate at post‐mortem. The study received ethical approval from the Cambridgeshire Local Research Ethics Committee No. 98/166.

Analysis of data

Incidence figures are presented as crude estimates with confidence intervals (CIs), together with age‐specific figures, and figures age‐standardized to the 1991 European population. Only those patients meeting the UK Brain Bank criteria for Parkinson’s disease were included in the analysis of cognitive deficits. Using our battery of cognitive tests, we have proposed a three‐stage procedure to evaluate the cognitive performance of these patients. This is based on their scores at the MMSE, the PRM task and the modified version of the TOL task. A MMSE of <24 was used to divide patients into two groups in the first instance (Tangalos et al., 1996). Patients were then classified as cognitively intact if they also performed well at the PRM and the TOL, or as having a predominant frontostriatal impairment if they were poor at the TOL task only, predominant temporal lobe impairment if they were poor at the PRM task only, or a global pattern of impairment if impaired at tests in both domains (Fig. 2). Greater than 1 SD below normative mean scores for the PRM has been taken as indicative of impairment (CANTAB data), i.e. a cut‐off score of <16/24. Age‐ and IQ‐matched normative data for the modified TOL suggests an appropriate cut‐off score of <8/14 (B. Sahakian, unpublished data; Lewis et al., 2003).

The validity of this three‐stage process as a useful discriminatory method of detecting different types of cognitive impairment in Parkinson’s disease has been explored using other cognitive domains: the verbal fluency for letters test (FAS), and, for animals, tasks sensitive to frontal lobe damage, and the SRM, which is sensitive to both frontal and temporal lobe deficits. Analysis of variance followed by post hoc pair‐wise comparisons have been used to evaluate the usefulness of distinguishing between these subgroups.

Results

Patient recruitment

Three hundred and ninety‐one patients with suggested newly diagnosed parkinsonism were identified during the entire study, including our 3‐month run in period. Of these, 73 had previously been diagnosed outside the 25‐month incidence period or were not resident in Cambridgeshire at the time of diagnosis and were thus excluded from this incidence study. Of the 318 remaining, seven patients were also excluded since further inpatient assessments and investigations confirmed non‐extrapyramidal diagnoses, including single cases of cord meningioma, motor neuron disease, chronic subdural haematoma, peripheral neuropathy, arthritis, depression, and Alzheimer’s disease. Two further patients were excluded because of resolution of all symptoms and signs without treatment or obvious cause.

Of the 309 incident cases of parkinsonism, 239 patients (77%) consented to participate in our assessment. Seventy patients were not seen due to death (n = 15), could not be contacted despite numerous attempts (n = 18), or refused to consent (n = 37). The referral source for the 309 patients is presented in Table 1 and their diagnoses are presented in Table 2. For the 70 patients not assessed, diagnoses were based on hospital notes and/or GP records only.

Incidence

Out of the 309 cases of parkinsonism, 201 were diagnosed as Parkinson’s disease meeting Brain Bank criteria (PDBB). Age‐ and sex‐specific incidence figures based on these 201 Parkinson’s disease cases and for the 309 parkinsonism cases are presented in Table 3 and Fig. 1. Prevalent cases (therefore not at risk of incident Parkinson’s disease) have not been excluded from the population denominator but are unlikely to substantially influence incidence estimates. Standardization to the 1991 European population age structure produces an incidence figure of 10.8 (CI 9.4–12.4) for Parkinson’s disease and of 16.6 (CI 14.8–18.6) for parkinsonism, per 100 000 population per year.

Clinical features including cognitive deficits

One hundred and fifty‐nine out of 201 Parkinson’s disease patients participated in our detailed assessments. Based on their age and sex distribution (Table 4), these 159 incident Cambridgeshire Parkinson’s disease patients appear to be representative of all patients identified in the incidence screen (Table 2). Figure 2 shows the cognitive performance of these 159 Parkinson’s disease patients. Thirteen of the 159 (8%) patients scored <24 on the MMSE and therefore had evidence of marked cognitive impairment. Patients with a history of visual hallucinations or fluctuating cognitive ability suggesting a clinical diagnosis of DLB have not been included in this report. (It is possible, however, that these features may not always be recalled or reported by patients or their carers; see Discussion.) Of the remaining 146 patients scoring 24 or above on the MMSE, four became too fatigued to continue or had inability to complete any of the computerized tests due to visual impairment. Thirty patients scored <16 on the PRM test, suggesting a temporal lobe type cognitive impairment, of whom 12 were able to perform the TOL satisfactorily. An additional 14/106 (13%) patients who scored well at the MMSE and PRM tasks were poor at the TOL, suggesting an isolated frontostriatal type pattern of impairment. We therefore have evidence of some form of cognitive impairment for 13 + 30 + 14 = 57/159 (36%) of patients assessed.

Based on these three tests only, we have classified 92 patients as cognitively intact, 14 + 3 = 17 patients as having a specific frontostriatal type deficit, 12 patients as having a specific temporal lobe type deficit, and 16 + 5 = 21 patients as having deficits in both domains (global impairment) (Fig. 2). Twenty‐two out of 159 (14%) of our patients had a Beck depression score >14, suggesting the presence of depression (Leentjens et al., 2000).

Patients with either a global or a frontal pattern of cognitive impairment were significantly older, had higher UPDRS motor scores, and had lower premorbid IQs than patients who were cognitively intact. There were no differences in their scores on the Beck depression inventory. In an attempt to validate these four patient subgroups, further analysis using spatial recognition memory and verbal fluency tasks confirmed significant differences in scores among these patient groups (Table 5). As predicted, patients classified with either frontostriatal or global cognitive impairment performed less well at our other frontal cognitive tasks than patients without cognitive impairments. Patients classified as having temporal lobe impairments did not differ from the cognitively unimpaired group at these other tests of frontal lobe function.

Discussion

This is the first study to present the incidence of Parkinson’s disease and the cognitive problems of a newly diagnosed cohort of Parkinson’s disease patients using a community‐based epidemiological approach. Phenotypic descriptions are far more useful when patient cohorts are derived from a resident population, as studies that have identified patients solely through movement disorder clinics will likely recruit a cohort of Parkinson’s disease patients skewed towards the young, the complicated or the interesting. Therefore, patients with late‐onset or straightforward disease may be under‐represented. Our age‐standardized incidence figures for Parkinson’s disease (10.8/105yr–1) and for parkinsonism (16.6/105yr–1) are similar to those for other European populations studied. In this cohort of incident Parkinson’s disease patients, 36% performed poorly in at least one of three cognitive tasks.

The frequency of Parkinson’s disease will vary widely depending on the choice of inclusion criteria, as demonstrated in the Olmstead county study (Bower et al., 2000), and we have therefore adopted the UK Brain Bank criteria (Hughes et al., 1992a, b) as this is regarded by many as the most reliable way of making the clinical diagnosis of Parkinson’s disease. The cornerstone of these clinical criteria is that the patients exhibit ‘bradykinesia’ in some form or other, and so its absence excludes the diagnosis of Parkinson’s disease. However, it is becoming more apparent from clinical series with follow‐up data that a set of patients with asymmetrical postural or resting tremors in the absence of bradykinesia or rigidity may progress to more typical forms of Parkinson’s disease responsive to dopaminergic therapy, many years after the onset of their disease (Pal et al., 2002). Indeed we have identified five patients with just such a presentation who, according to UK Brain Bank criteria would not have had Parkinson’s disease as their initial diagnosis, but who ultimately met these criteria. Overlap between isolated postural tremor and Parkinson’s disease is further exemplified by a recent study of PARK4 patients, where some individuals have a postural tremor only, whilst other relatives with the same ‘at risk gene’ have typical Parkinson’s disease (Farrer et al., 1999).

Nevertheless the recent re‐evaluation of the clinical diagnoses of Parkinson’s disease by the authors of the Brain Bank criteria suggests that the positive predictive value of clinical diagnoses is high (98.6%), but that false negative cases suggest a broader clinical picture of disease than previously thought (Hughes et al., 2002). Whilst we accept the limitation of using these criteria, they were nevertheless adopted in our study so we can make comparisons between this and other studies. Our incidence figure for Parkinson’s disease may, however, be an underestimate since a proportion of our atypical or unspecified parkinsonism patients are likely to have typical Parkinson’s disease at post‐mortem. Although the study attempted to identify all forms of parkinsonism, it is likely that underascertainment of non‐Parkinson’s disease diagnoses such as essential tremor occurred, as this condition is less likely to present to medical attention. The low frequency of progressive supranuclear palsy and multiple system atrophy within our cohort is also probably due to hitherto undiagnosed patients within the atypical parkinsonism group.

Previous studies of Parkinson’s disease incidence within the UK have used GP and hospital records to estimate incidence figures retrospectively (Brewis et al., 1966; Sutcliffe and Meara, 1995) or have been based among smaller urban populations likely to have higher rates of population migration (Cockerell et al., 1996; MacDonald et al., 2000). The present study is the first UK study that has prospectively ascertained and assessed new diagnoses of Parkinson’s disease and parkinsonism among a large, stable population base. In contrast to some records‐based studies (D’Alessandro et al., 1987; Milanov et al., 2001) but consistent with others using screening methods of case ascertainment (de Rijk et al., 1997), we find no decline in the frequency of disease in the highest age groups, suggesting that we have reasonable case ascertainment in the older age groups, who are less often identified in epidemiological research. Our large population denominator has allowed us to identify large absolute numbers of cases in all of the older age groups, giving us greater precision in incidence estimates, and thus narrower confidence intervals. Age‐specific incidence rates in this study are similar in the two sexes below the age of 70 years, with an excess incidence in men above this age. This is similar to the findings of previous screening studies (Tandberg et al., 1995; de Rijk et al., 1997) and the larger records‐based studies (Kuopio et al., 1999; Van Den Eeden et al., 2003) and might suggest that sex‐specific Parkinson’s disease risk factors are most relevant for later‐onset disease. Sex differences in disease risk and/or phenotype might be explained by the protective effects of sex hormones (for a review see Sawada and Shimohama, 2003), or by the influence of environmental or occupational risk factors to which men and women have differential exposures.

Door‐to‐door screening has been used as a method of identifying a population‐based cohort of patients. Such studies may, however, be limited by low response rates and the validity of the initial screening questionnaire (Bermejo et al., 2001). Since we aimed to recruit a large number of incident Parkinson’s disease patients in order to explore variable phenotypes, a door‐to‐door screening approach was considered less practical than targeting multiple sources. All of our five sources contributed large numbers of cases to the study. Inevitably, however, we recognize that some cases will have been missed. Capture–recapture analysis has been previously proposed as a method of estimating the number of cases not identified in a study using multiple sources of case ascertainment. This technique relies on source independence and the randomness of identification of cases from each source (Tilling and Sterne, 1999). Only 51/309 of our parkinsonism patients were identified from two or more sources. It became clear during the study that no patients were being seen in both neurology and geriatric outpatient clinics, and that, following GP referral for assessment in the study, neurologists, geriatricians and Parkinson’s disease nurses would not subsequently re‐notify the study if and when the patient came to their attention. The prerequisites for performing a capture–recapture analysis were therefore not met, and so we have not attempted to perform this.

Four per cent of our cohort of incident Parkinson’s disease cases had more than two first‐degree relatives with features of parkinsonism as reported by the proband, although if we include second‐degree relatives 20% of our incident cohort have a family history of the disease (Table 6). Only one of our incident Parkinson’s disease patients was diagnosed below the age of 40 years, suggesting that young onset forms of the disease are, in fact, very rare. Given that it is this group that has the highest risk of carrying parkin‐related disease (Lucking et al., 2000), our study is unlikely to be influenced by inclusion of parkin‐related cases.

In this population‐based cohort of incident Parkinson’s disease patients, 36% performed poorly in at least one of three cognitive tasks. Follow‐up of prevalent cases has estimated that between 20% (Brown and Marsden, 1984) and 75% (Aarsland et al., 2003) of Parkinson’s disease patients will ultimately develop dementia. However, the frequency of the wider range of cognitive impairments at incidence has not previously been assessed. The threshold used to define cognitive impairment is always inevitably somewhat arbitrary, but a score below 24 on the MMSE has been previously accepted as indicative of cognitive impairment (Tangalos et al., 1996) and scores of 16/24 on the PRM and 8/14 on the TOL are greater than 1 SD below expected for unaffected age‐ and IQ‐matched individuals in Cambridgeshire (B.Sahakian unpublished data). We have used data from age‐ and IQ‐matched volunteers to derive these cut‐off estimates for impairment, but there is always concern that data from volunteers do not represent the normal level of functioning among a true population‐based cohort. Despite this concern, these thresholds, which we have used to identify cognitive impairment, are very low, and therefore are unlikely to misclassify individuals with intact cognitive ability.

Our cognitively intact subjects were younger at diagnosis and had significantly higher estimated premorbid IQ scores (based on the NART test) than those with cognitive impairment. This might suggest that older age at disease onset is a risk factor for cognitive impairment, although in this analysis we have not made adjustment for the background effects of ageing. While some patients may have been misclassified as cognitively impaired due to a genuinely low premorbid IQ, without further follow‐up, we cannot be sure that performance on the NART test is completely uninfluenced by the disease process. Patients with frontal or global types of cognitive impairment also had significantly higher UPDRS motor scores than patients without cognitive impairment. However, they had similar duration from onset of motor symptoms, suggesting that the patients with cognitive impairment had a more aggressive form of the disease.

The relationship between performance at our cognitive tasks and regional cortical dysfunction is the subject of ongoing studies. For example, imaging data suggest involvement of the dorsolateral prefrontal and anterior cingulate cortices and the caudate nucleus in normal individuals performing the TOL (Dagher et al., 1999), and that further areas may be recruited in the presence of Parkinson’s disease (Dagher et al., 2001). In addition, parietal cortical areas have also been seen to activate during this task, suggesting the presence of wider cortical circuits (Baker et al., 1996). The importance of the dorsolateral prefrontal cortex in performing the TOL is, however, clear, exemplified by the observation that patients with parietal lesions have no problems performing the TOL task (M, Mehta, B. Sahakian, T. W. Robbins, unpublished data), whereas patients with frontal lobe lesions do (Owen et al., 1990). We recognize that identification of region or circuit‐specific subtypes of cognitive impairment among patients can only be made with certainty following serial tests of cognition that use the same cortical circuits. However, comparisons of our three groups of impaired patients with our unimpaired patients using tests of verbal fluency and spatial recognition confirmed that those classified as frontally or globally impaired on the basis of MMSE, PRM and TOL were indeed less able to perform other frontal tasks. Patients with a temporal lobe pattern of impairment were no different from the cognitively intact group at frontal lobe tasks.

The descriptive results presented here suggest that a range of cognitive impairment is common even in the early stages of Parkinson’s disease. We have limited our analysis to patients with Parkinson’s disease and excluded patients meeting clinical criteria for DLB. DLB patients are currently distinguished from Parkinson’s disease + dementia patients (PDD) by the respective timing at which cognitive impairment occurs in relation to the symptomatic onset of parkinsonism. A minimum of 12 months with ‘motor‐only’ symptoms is recommended to define PDD (McKeith et al., 1996), but consensus criteria do not give guidance of how to retrospectively time the onset of symptoms of dementia, even though both the cognitive and motor symptoms of parkinsonism often develop insidiously. Since the presence of visual hallucinations or fluctuating cognitive ability may not be reliably reported by patients or carers (McKeith et al., 1999), some DLB patients may be misclassified after a single assessment as Parkinson’s disease. There are therefore some conceptual problems distinguishing between patients with DLB and PDD, although all patients reporting less than 12 months of ‘motor‐only’ symptoms before demonstrating marked cognitive deficits in this study have been classified as DLB and excluded from this cognitive analysis. It is likely that, in reality, considerable overlap between these groups exists (Ballard et al., 2002).

Scores of <24 at the MMSE (8%) or scores of <16 at the PRM and <8 at the TOL are seen in 13 + 16 = 29/159 (18%) of our incident patients, which may suggest the presence of diffuse Lewy bodies in cortical regions (Apaydin et al., 2002), may represent specific anterior cingulate cortex or caudate nucleus involvement (Ito et al., 2002) or may also represent the concurrent development of Alzheimer pathology (Hughes et al., 1993). Isolated frontostriatal‐type impairments are also seen in a further 17/159 (11%) of our cohort and may represent dopaminergic deficiency of the dorsolateral prefrontal cortex (Cools et al., 2002) or may also be part of a prodromal period heralding the onset of dementia (Woods and Troster, 2003). Eight per cent of our Parkinson’s disease patients had isolated impairment in temporal lobe function based on the PRM test. Previous studies of Parkinson’s disease patients derived from clinical series have shown apparently conflicting PRM data due to inclusion of patients with differing dementia ratings (Sahakian et al., 1988; Owen et al., 1993). However, recent imaging studies (Hu et al., 2000; Camicioli et al., 2003) and pathological studies (Braak et al., 2000) suggest that temporal lobe dysfunction does indeed occur in some Parkinson’s disease patients with the presence of Lewy bodies, Lewy neuritis and Alzheimer changes (Braak et al., 2000). None of our results seem to be due to a differential presence of depression among the groups. There will inevitably be a large number of variables, including the variety of drug treatments used for Parkinson’s disease, which may have independent or interacting effects on cognitive ability. However, in this account we have deliberately kept the description of these patients simple as this gives the most accurate account of the population identified. All of our patients will be followed up to look at how their cognitive impairments develop.

Comparing the incidence figure from this study with those previously produced suggests that there is reasonable uniformity of incidence of Parkinson’s disease among European populations. Incidence studies with good methodology and presentation of age‐ and sex‐specific figures among non‐Caucasian populations are, however, still required to confirm whether other populations have similar or different rates of disease. Future studies should where possible also perform phenotypic assessments (including cognitive assessments) on their patients and collect DNA samples to make future epidemiological and genotypic/phenotypic comparisons possible.

Acknowledgements

T.F. was supported by a clinical training fellowship from the Wellcome Trust and a Raymond and Beverley Sackler studentship.

Fig. 1 Graphical representation of the age‐specific figures for Parkinson’s disease and parkinsonism in the CamPaiGN study.

Fig. 1 Graphical representation of the age‐specific figures for Parkinson’s disease and parkinsonism in the CamPaiGN study.

Fig. 2 Flowchart to show the abilities of our 159 Parkinson’s disease patients at the MMSE, followed by the pattern recognition task and the Tower of London task. Conclusions regarding cognitive abilities are based on 142 patients with outcomes for all three tasks. Patients with fatigue or visual impairment did not perform all cognitive tests.

Fig. 2 Flowchart to show the abilities of our 159 Parkinson’s disease patients at the MMSE, followed by the pattern recognition task and the Tower of London task. Conclusions regarding cognitive abilities are based on 142 patients with outcomes for all three tasks. Patients with fatigue or visual impairment did not perform all cognitive tests.

Table 1

Sources of initial case ascertainment

Primary referral No. of patients assessed No. of patients not assessed Total Subsequently identified by 2nd source 
GP 66 72 
Neurologist 91 16 107 15 
Geriatrician 54 12 66 15 
Parkinson’s disease nurse 13 17 
Hospital discharge 15 32 47 
Total 239 70 309 51 
Primary referral No. of patients assessed No. of patients not assessed Total Subsequently identified by 2nd source 
GP 66 72 
Neurologist 91 16 107 15 
Geriatrician 54 12 66 15 
Parkinson’s disease nurse 13 17 
Hospital discharge 15 32 47 
Total 239 70 309 51 
Table 2

Clinical diagnoses among our incident cases of parkinsonism

Extrapyramidal diagnosis n Assessed/not assessed  Male/female Mean age at diagnosis: years (range) 
PDBB 201 159/42 105/96 72.0 (37–94) 
Drug‐induced parkinsonism 32 23/9 16/16 72.5 (51–92) 
Atypical Parkinson’s disease 16 16/0 10/6 71.5 (43–88) 
Dementia with Lewy bodies 16 13/3 10/6 77.4 (68–89) 
Essential tremor 13 11/2 5/8 65.9 (40–93) 
Unspecified parkinsonism 12 0/12 6/6 70.9 (44–89) 
Vascular parkinsonism 10 10/0 5/5 77.0 (67–87) 
Dystonic tremor 4/0 1/3 57.0 (40–70) 
Corticobasal degeneration 2/0 0/2 65.4 (61–70) 
Multiple system atrophy 1/0 0/1 47.4 
Progressive supranuclear palsy 0/1 1/0 72.7 
Orthostatic tremor 0/1 0/1 70.7 
Extrapyramidal diagnosis n Assessed/not assessed  Male/female Mean age at diagnosis: years (range) 
PDBB 201 159/42 105/96 72.0 (37–94) 
Drug‐induced parkinsonism 32 23/9 16/16 72.5 (51–92) 
Atypical Parkinson’s disease 16 16/0 10/6 71.5 (43–88) 
Dementia with Lewy bodies 16 13/3 10/6 77.4 (68–89) 
Essential tremor 13 11/2 5/8 65.9 (40–93) 
Unspecified parkinsonism 12 0/12 6/6 70.9 (44–89) 
Vascular parkinsonism 10 10/0 5/5 77.0 (67–87) 
Dystonic tremor 4/0 1/3 57.0 (40–70) 
Corticobasal degeneration 2/0 0/2 65.4 (61–70) 
Multiple system atrophy 1/0 0/1 47.4 
Progressive supranuclear palsy 0/1 1/0 72.7 
Orthostatic tremor 0/1 0/1 70.7 

PDBB = Parkinson’s disease cases meeting Brain Bank criteria.

Table 3

Age‐ and sex‐specific incidence figures for Parkinson’s disease and parkinsonism in the CamPaiGN study

Cambridgeshire population, 2001 All ages 30–39 years 40–49 years 50–59 years 60–69 years 70–79 years 80+ years 
Men 349 678 55 537 48 372 45 088 30 467 21 506 9382 
Women 359 037 55 933 48 648 45 211 31 269 26 183 17 890 
All 708 715 111 470 97 020 90 299 61 736 47 689 27 272 
Parkinson’s disease incidence/105yr–1        
Men 14.4 0.9 3.0 8.5 41.0 98.2 117.7 
Women 12.8 0.9 1.0 10.6 41.4 56.8 70.0 
All (CI) 13.6 (11.8–15.6) 0.9 (0.22–3.6) 2.0 (0.75–5.3) 9.6 (6.0–15.2) 41.2 (31.5–53.9) 75.5 (60.2–94.6) 86.2 (65.1–114.1) 
Parkinsonism incidence/105yr–1        
Men 21.8 1.7 6.0 13.8 58.3 145.1 184.2 
Women 20.0 1.7 3.9 15.9 59.9 89.8 110.0 
All (CI) 20.9 (18.7–23.3) 1.7 (0.6–4.5) 4.9 (2.6–9.1) 14.9 (10.3–21.6) 59.1 (47.2–73.9) 114.7 (95.5–137.8) 135.5 (108.4–169.4) 
Cambridgeshire population, 2001 All ages 30–39 years 40–49 years 50–59 years 60–69 years 70–79 years 80+ years 
Men 349 678 55 537 48 372 45 088 30 467 21 506 9382 
Women 359 037 55 933 48 648 45 211 31 269 26 183 17 890 
All 708 715 111 470 97 020 90 299 61 736 47 689 27 272 
Parkinson’s disease incidence/105yr–1        
Men 14.4 0.9 3.0 8.5 41.0 98.2 117.7 
Women 12.8 0.9 1.0 10.6 41.4 56.8 70.0 
All (CI) 13.6 (11.8–15.6) 0.9 (0.22–3.6) 2.0 (0.75–5.3) 9.6 (6.0–15.2) 41.2 (31.5–53.9) 75.5 (60.2–94.6) 86.2 (65.1–114.1) 
Parkinsonism incidence/105yr–1        
Men 21.8 1.7 6.0 13.8 58.3 145.1 184.2 
Women 20.0 1.7 3.9 15.9 59.9 89.8 110.0 
All (CI) 20.9 (18.7–23.3) 1.7 (0.6–4.5) 4.9 (2.6–9.1) 14.9 (10.3–21.6) 59.1 (47.2–73.9) 114.7 (95.5–137.8) 135.5 (108.4–169.4) 
Table 4

Description of the phenotypes of 159 Parkinson’s disease patients assessed in this study

 Male Female All 
n 85 74 159 
Ethnic origin  82 Caucasian  156 Caucasian 
 1 Afro‐Caribbean 74 Caucasian 1 Afro‐Caribbean 
 2 Asian  2 Asian 
Premorbid IQ    
 Mean 109 109 109 
 Range (86–126) (89–124)  
Age at onset (years)    
 Mean 67.3 68.2 67.8 
 Range (14.5–89.2) (42.0–88.3)  
Age at diagnosis (years)    
 Mean 69.9 70.7 70.3 
 Range (37.7–89.6) (46.8–90.2)  
Age at assessment (years)    
 Mean 70.3 71.0 70.6 
 Range (37.8–90.3) (47.2–90.4)  
UPDRS motor score    
 Mean 25.7 26.0 25.9 
 Range (4–61) (4.5–58)  
HY stage    
 Mean 2.0 2.0 2.0 
 Range (1–5) (1–5)  
MMSE    
 Mean 27.3 27.4 27.3 
 Range (16–30) (11–30)  
Parkinson’s disease medication    
 Treated 44 31 75 
 Untreated 41  43  84  
 Male Female All 
n 85 74 159 
Ethnic origin  82 Caucasian  156 Caucasian 
 1 Afro‐Caribbean 74 Caucasian 1 Afro‐Caribbean 
 2 Asian  2 Asian 
Premorbid IQ    
 Mean 109 109 109 
 Range (86–126) (89–124)  
Age at onset (years)    
 Mean 67.3 68.2 67.8 
 Range (14.5–89.2) (42.0–88.3)  
Age at diagnosis (years)    
 Mean 69.9 70.7 70.3 
 Range (37.7–89.6) (46.8–90.2)  
Age at assessment (years)    
 Mean 70.3 71.0 70.6 
 Range (37.8–90.3) (47.2–90.4)  
UPDRS motor score    
 Mean 25.7 26.0 25.9 
 Range (4–61) (4.5–58)  
HY stage    
 Mean 2.0 2.0 2.0 
 Range (1–5) (1–5)  
MMSE    
 Mean 27.3 27.4 27.3 
 Range (16–30) (11–30)  
Parkinson’s disease medication    
 Treated 44 31 75 
 Untreated 41  43  84  

HN = Hohn and Yahr.

Table 5

Comparison of four subgroups of Parkinson’s disease patients on the basis of cognitive ability

 Cognitively intact Frontostriatal deficits (TOL task) Temporal lobe type deficits (PRM task) Frontostriatal and temporal lobe type deficits (TOL + PRM) Anova P value (df) 
n 92 17 12 21  
Age diagnosed (years)      
 Mean 66.5 74.0 70.7 76.4 <0.001 
 Range (37–83.7) (63.3‐ 80.9) (53.6‐ 82.5) (60.5–87.3) (3) 
UPDRS motor      
 Mean 21.9 32.6 23.3 33.8 <0.001 
 Range (4.0‐ 50.5) (4.0–54.5) (8.0–56.5) (5.5–58.0) (3) 
Duration since symptom onset       
 Mean 3.1 2.2 2.3 2.2 0.74 
 Range (0.4‐ 38.2) (0.2‐ 6.2) (0.7–5.4) (0.4–13.8) (3) 
NART      
 Mean score 112 106 103 100 <0.001 
 Range (86–126) (90–121) (89–125) (86–124) (3) 
SRM      
 Mean score 16.0 13.0 14.8 11.8 <0.001 
 Range (3–20) (9–18) (11–18) (0–18) (3) 
FAS fluency       
 Mean score 37.3 30.5* 32.3 22.8 <0.001 
 Range (17–67) (9–60) (21–56) (2–45) (3) 
Animal fluency      
 Mean score 22.7 15.3 19.3 13.6 <0.001 
 Range (10–46) (8–26) (10–44) (8–26) (3) 
BDI score      
Mean score 7.4 8.7 7.6 7.4 0.88 
 Range (0–24) (2–19) (1–20) (0–25) (3) 
 Cognitively intact Frontostriatal deficits (TOL task) Temporal lobe type deficits (PRM task) Frontostriatal and temporal lobe type deficits (TOL + PRM) Anova P value (df) 
n 92 17 12 21  
Age diagnosed (years)      
 Mean 66.5 74.0 70.7 76.4 <0.001 
 Range (37–83.7) (63.3‐ 80.9) (53.6‐ 82.5) (60.5–87.3) (3) 
UPDRS motor      
 Mean 21.9 32.6 23.3 33.8 <0.001 
 Range (4.0‐ 50.5) (4.0–54.5) (8.0–56.5) (5.5–58.0) (3) 
Duration since symptom onset       
 Mean 3.1 2.2 2.3 2.2 0.74 
 Range (0.4‐ 38.2) (0.2‐ 6.2) (0.7–5.4) (0.4–13.8) (3) 
NART      
 Mean score 112 106 103 100 <0.001 
 Range (86–126) (90–121) (89–125) (86–124) (3) 
SRM      
 Mean score 16.0 13.0 14.8 11.8 <0.001 
 Range (3–20) (9–18) (11–18) (0–18) (3) 
FAS fluency       
 Mean score 37.3 30.5* 32.3 22.8 <0.001 
 Range (17–67) (9–60) (21–56) (2–45) (3) 
Animal fluency      
 Mean score 22.7 15.3 19.3 13.6 <0.001 
 Range (10–46) (8–26) (10–44) (8–26) (3) 
BDI score      
Mean score 7.4 8.7 7.6 7.4 0.88 
 Range (0–24) (2–19) (1–20) (0–25) (3) 

Analysis of variance followed by pairwise comparisons with cognitively unimpaired group. Significantly different from cognitively unimpaired group (P < 0.001); significantly different from cognitively unimpaired group (P < 0.01); *significantly different from cognitively unimpaired group (P < 0.05).

Table 6

Frequency of positive family history among 159 Parkinson’s disease patients

Family history of Parkinson’s disease No. (%) Mean age at diagnosis of proband (years) 
>2 FDR with parkinsonism 7/159 (4%) 72.0 (range 64.0–76.5) 
=1 FDR with parkinsonism 26/159 (16%) 68.9 (range 50.5–81.9) 
=1 FDR or SDR with parkinsonism 32/159 (20%) 68.7 (range 50.5–84.8) 
Family history of Parkinson’s disease No. (%) Mean age at diagnosis of proband (years) 
>2 FDR with parkinsonism 7/159 (4%) 72.0 (range 64.0–76.5) 
=1 FDR with parkinsonism 26/159 (16%) 68.9 (range 50.5–81.9) 
=1 FDR or SDR with parkinsonism 32/159 (20%) 68.7 (range 50.5–84.8) 

FDR = first‐degree relative (parent, offspring, sibling); SDR = second‐degree relative (grandparent, uncle, aunt, nephew, niece)

References

Aarsland D, Tandberg E, Larsen JP, Cummings JL. Frequency of dementia in Parkinson disease.
Arch Neurol
 
1996
;
53
:
538
–42.
Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh‐Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8‐year prospective study.
Arch Neurol
 
2003
;
60
:
387
–92.
Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW. Parkinson disease neuropathology: later‐developing dementia and loss of the levodopa response.
Arch Neurol
 
2002
;
59
:
102
–12.
Baker SC, Rogers RD, Owen AM, Frith CD, Dolan RJ, Frackowiak RS, et al. Neural systems engaged by planning: a PET study of the Tower of London task.
Neuropsychologia
 
1996
;
34
:
515
–26.
Ballard CG, Aarsland D, McKeith I, O’Brien J, Gray A, Cormack F, et al. Fluctuations in attention: PD dementia vs DLB with parkinsonism.
Neurology
 
2002
;
59
:
1714
–20.
Benton AL. Differential behavioural effects of frontal lobe disease.
Neuropsychologia
 
1968
;
6
:
53
–60.
Bermejo F, Gabriel R, Vega S, Morales JM, Rocca WA, Anderson DW. Problems and issues with door‐to‐door, two‐phase surveys: an illustration from central Spain.
Neuroepidemiology
 
2001
;
20
:
225
–31.
Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990.
Neurology
 
1999
;
52
:
1214
–20.
Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Influence of strict, intermediate, and broad diagnostic criteria on the age‐ and sex‐specific incidence of Parkinson’s disease.
Mov Disord
 
2000
;
15
:
819
–25.
Braak H, Del Tredici K, Bohl J, Bratzke H, Braak E. Pathological changes in the parahippocampal region in select non‐Alzheimer’s dementias.
Ann NY Acad Sci
 
2000
;
911
:
221
–39.
Brewis M, Poskanzer DC, Rolland C, Miller H. Neurological disease in an English city.
Acta Neurol Scand
 
1966
;
42
Suppl 24:
1
–89.
Brown RG, Marsden CD. How common is dementia in Parkinson’s disease?
Lancet
 
1984
;
2
:
1262
–5.
Camicioli R, Moore MM, Kinney A, Corbridge E, Glassberg K, Kaye JA. Parkinson’s disease is associated with hippocampal atrophy.
Mov Disord
 
2003
;
18
:
784
–90.
Chen RC, Chang SF, Su CL, Chen TH, Yen MF, Wu HM, et al. Prevalence, incidence, and mortality of PD: a door‐to‐door survey in Ilan county, Taiwan.
Neurology
 
2001
;
57
:
1679
–86.
Cockerell OC, Goodridge DM, Brodie D, Sander JW, Shorvon SD. Neurological disease in a defined population: the results of a pilot study in two general practices.
Neuroepidemiology
 
1996
;
15
:
73
–82.
Cools R, Stefanova E, Barker RA, Robbins TW, Owen AM. Dopaminergic modulation of high‐level cognition in Parkinson’s disease: the role of the prefrontal cortex revealed by PET.
Brain
 
2002
;
125
:
584
–94.
D’Alessandro R, Gamberini G, Granieri E, Benassi G, Naccarato S, Manzaroli D. Prevalence of Parkinson’s disease in the Republic of San Marino.
Neurology
 
1987
;
37
:
1679
–82.
Dagher A, Owen AM, Boecker H, Brooks DJ. Mapping the network for planning: a correlational PET activation study with the Tower of London task.
Brain
 
1999
;
122
:
1973
–87.
Dagher A, Owen AM, Boecker H, Brooks DJ. The role of the striatum and hippocampus in planning: a PET activation study in Parkinson’s disease.
Brain
 
2001
;
124
:
1020
–32.
de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez‐Pousa S, et al. Prevalence of parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson’s disease.
J Neurol Neurosurg Psychiatry
 
1997
;
62
:
10
–5.
Dubois B, Pillon B. Cognitive deficits in Parkinson’s disease.
J Neurol
 
1997
;
244
:
2
–8.
Dupont E. Epidemiology of parkinsonism. In: The Parkinson investigation. Symposium on Parkinsonism. Copenhagen, Denmark: Merck Sharp Dohme;
1977
. p.
65
–75.
Fahn S, Elton RL, UPDRS Development Committee. Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent developments in Parkinson’s disease. Florham Park (NJ): MacMillan Healthcare Information;
1987
. p.
153
–63
Fall PA, Axelson O, Fredriksson M, Hansson G, Lindvall B, Olsson JE, et al. Age‐standardized incidence and prevalence of Parkinson’s disease in a Swedish community.
J Clin Epidemiol
 
1996
;
49
:
637
–41.
Farrer M, Gwinn‐Hardy K, Muenter M, DeVrieze FW, Cook R, Perez‐Tur J, et al. A chromosome 4p haplotype segregating with Parkinson’s disease and postural tremor.
Hum Mol Genet
 
1999
;
8
:
81
–5.
Folstein MF, Folstein SE, McHugh PR. ‘Mini‐mental state’. A practical method for grading the cognitive state of patients for the clinician.
J Psychiatr Res
 
1975
;
12
:
189
–98.
Foltynie T, Brayne C, Barker RA. The heterogeneity of idiopathic Parkinson’s disease.
J Neurol
 
2002
;
249
:
138
–45.
Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease.
J Neurol Neurosurg Psychiatry
 
1988
;
51
:
745
–52.
Goodglass H. The assessment of aphasia and related disorders. Philadelphia: Lea and Febiger;
1972
.
Granieri E, Carreras M, Casetta I, Govoni V, Tola MR, Paolino E, et al. Parkinson’s disease in Ferrara, Italy, 1967 through 1987.
Arch Neurol
 
1991
;
48
:
854
–7.
Hobson P, Meara J. The detection of dementia and cognitive impairment in a community population of elderly people with Parkinson’s disease by use of the CAMCOG neuropsychological test.
Age Ageing
 
1999
;
28
:
39
–43.
Hofman A, Collette HJ, Bartelds AI. Incidence and risk factors of Parkinson’s disease in The Netherlands.
Neuroepidemiology
 
1989
;
8
:
296
–9.
Horstink MW, Morrish PK. Preclinical diagnosis of Parkinson’s disease.
Adv Neurol
 
1999
;
80
:
327
–333.
Hu MT, Taylor‐Robinson SD, Chaudhuri KR, Bell JD, Labbe C, Cunningham VJ, et al. Cortical dysfunction in non‐demented Parkinson’s disease patients: a combined (31)P‐MRS and (18)FDG‐PET study.
Brain
 
2000
;
123
:
340
–52.
Hughes AJ, Ben Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathologic study.
Neurology
 
1992
a;
42
:
1142
–6.
Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico‐pathological study of 100 cases.
J Neurol Neurosurg Psychiatry
 
1992
b;
55
:
181
–4.
Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson’s disease.
Arch Neurol
 
1993
;
50
:
140
–8.
Hughes AJ, Daniel SE, Ben Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service.
Brain
 
2002
;
125
:
861
–70.
Ito K, Nagano‐Saito A, Kato T, Arahata Y, Nakamura A, Kawasumi Y, et al. Striatal and extrastriatal dysfunction in Parkinson’s disease with dementia: a 6‐[18F]fluoro‐L‐dopa PET study.
Brain
 
2002
;
125
:
1358
–65.
Janvin C, Aarsland D, Larsen JP, Hugdahl K. Neuropsychological profile of patients with Parkinson’s disease without dementia.
Dement Geriatr Cogn Disord
 
2003
;
15
:
126
–31.
Jenkins AC. Epidemiology of parkinsonism in Victoria.
Med J Aust
 
1966
;
2
:
496
–502.
Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson’s Disease Questionnaire (PDQ‐39): development and validation of a Parkinson’s disease summary index score.
Age Ageing
 
1997
;
26
:
353
–7.
Kuopio AM, Marttila RJ, Helenius H, Rinne UK. Changing epidemiology of Parkinson’s disease in southwestern Finland.
Neurology
 
1999
;
52
:
302
–8.
Kurland LT. Epidemiology: incidence, geographic distribution and genetic considerations. Springfield (IL): Fieldz, WS;
1958
.
Leentjens AF, Verhey FR, Luijckx GJ, Troost J. The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson’s disease.
Mov Disord
 
2000
;
15
:
1221
–4.
Lees AJ, Smith E. Cognitive deficits in the early stages of Parkinson’s disease.
Brain
 
1983
;
106
:
257
–70.
Lewis SJ, Cools R, Robbins TW, Dove A, Barker RA, Owen AM. Using executive heterogeneity to explore the nature of working memory deficits in Parkinson’s disease.
Neuropsychologia
 
2003
;
41
:
645
–54.
Lucking CB, Durr A, Bonifati V, Vaughan J, De Michele G, Grassier T, et al. Association between early‐onset Parkinson’s disease and mutations in the parkin gene. French Parkinson’s Disease Genetics Study Group.
New Engl J Med
 
2000
;
342
:
1560
–7.
MacDonald BK, Cockerell OC, Sander JW, Shorvon SD. The incidence and lifetime prevalence of neurological disorders in a prospective community‐based study in the UK.
Brain
 
2000
;
123
:
665
–76.
Marttila RJ, Rinne UK. Dementia in Parkinson’s disease.
Acta Neurol Scand
 
1976
;
54
:
431
–41.
Mayeux R, Denaro J, Hemenegildo N, Marder K, Tang MX, Cote LJ, et al. A population‐based investigation of Parkinson’s disease with and without dementia. Relationship to age and gender.
Arch Neurol
 
1992
;
49
:
492
–7.
Mayeux R, Marder K, Cote LJ, Denaro J, Hemenegildo N, Mejia H, et al. The frequency of idiopathic Parkinson’s disease by age, ethnic group, and sex in northern Manhattan, 1988–1993.
Am J Epidemiol
 
1995
;
142
:
820
–7.
McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.
Neurology
 
1996
;
47
:
1113
–24.
McKeith IG, Perry EK, Perry RH. Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies.
Neurology
 
1999
;
53
:
902
–5.
Milanov I, Kmetska K, Karakolev B, Nedialkov E. Prevalence of Parkinson’s disease in Bulgaria.
Neuroepidemiology
 
2001
;
20
:
212
–4.
Miller E. Possible frontal impairments in Parkinson’s disease: a test using a measure of verbal fluency.
Br J Clin Psychol
 
1985
;
24
:
211
–2.
Morens DM, Davis JW, Grandinetti A, Ross GW, Popper JS, White LR. Epidemiologic observations on Parkinson’s disease: incidence and mortality in a prospective study of middle‐aged men.
Neurology
 
1996
;
46
:
1044
–50.
Morioka S, Sakata K, Yoshida S, Nakai E, Shiba M, Yoshimura N, et al. Incidence of Parkinson disease in Wakayama.
Japan J Epidemiol
 
2002
;
12
:
403
–7.
Nelson HE, O’Connell A. Dementia: the estimation of premorbid intelligence levels using the New Adult Reading Test.
Cortex
 
1978
;
14
:
234
–44.
60.
Office of National Statistics. Available from: http://www.statistics.gov.uk
Owen AM, Downes JJ, Sahakian BJ, Polkey CE, Robbins TW. Planning and spatial working memory following frontal lobe lesions in man.
Neuropsychologia
 
1990
;
28
:
1021
–34.
Owen AM, James M, Leigh PN, Summers BA, Marsden CD, Quinn NP, et al. Frontostriatal cognitive deficits at different stages of Parkinson’s disease.
Brain
 
1992
;
115
:
1727
–51.
Owen AM, Beksinska M, James M, Leigh PN, Summers BA, Marsden CD, et al. Visuospatial memory deficits at different stages of Parkinson’s disease.
Neuropsychologia
 
1993
;
31
:
627
–44.
Owen AM, Sahakian B, Hodges JR, Summers BA, Polkey CE, Robbins TW. Dopamine‐dependent frontostriatal planning deficits in early Parkinson’s disease.
Neuropsychology
 
1995
a;
9
:
126
–40.
Owen AM, Sahakian BJ, Semple J, Polkey CE, Robbins TW. Visuo‐spatial short‐term recognition memory and learning after temporal lobe excisions, frontal lobe excisions or amygdalo‐hippocampectomy in man.
Neuropsychologia
 
1995
b;
33
:
1
–24.
Pal S, Peng R, Brooks DJ, Rao CS, RayChaudhuri K. Isolated asymmetric dominantly inherited postural tremor with or without resting tremor: a variant presentation of long latency tremulous Parkinson’s disease? A clinical follow up [abstract].
J Neurol Neurosurg Psychiatry
 
2002
;
73
:
215
.
Richter P, Werner J, Heerlein A, Kraus A, Sauer H. On the validity of the Beck Depression Inventory. A review.
Psychopathology
 
1998
;
31
:
160
–8.
Robbins TW, James M, Owen AM, Sahakian BJ, McInnes L, Rabbitt P. Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers.
Dementia
 
1994
;
5
:
266
–81.
Robertson N, Deans J, Fraser M, Compston DA. Multiple sclerosis in south Cambridgeshire: incidence and prevalence based on a district register.
J Epidemiol Community Health
 
1996
;
50
:
274
–9.
Robertson NP, Deans J, Compston DA. Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England.
J Neurol Neurosurg Psychiatry
 
1998
;
65
:
492
–6.
Sahakian BJ, Morris RG, Evenden JL, Heald A, Levy R, Philpot M, et al. A comparative study of visuospatial memory and learning in Alzheimer‐type dementia and Parkinson’s disease.
Brain
 
1988
;
111
:
695
–718.
Sawada H, Shimohama S. Estrogens and Parkinson disease: novel approach for neuroprotection.
Endocrine
 
2003
;
21
:
77
–9.
Sutcliffe RL, Meara JR. Parkinson’s disease epidemiology in the Northampton District, England, 1992.
Acta Neurol Scand
 
1995
;
92
:
443
–50.
Tandberg E, Larsen JP, Nessler EG, Riise T, Aarli JA. The epidemiology of Parkinson’s disease in the county of Rogaland, Norway.
Mov Disord
 
1995
;
10
:
541
–9.
Tangalos EG, Smith GE, Ivnik RJ, Petersen RC, Kokmen E, Kurland LT, et al. The Mini‐Mental State Examination in general medical practice: clinical utility and acceptance.
Mayo Clin Proc
 
1996
;
71
:
829
–37.
Taylor AE, Saint‐Cyr JA, Lang AE. Frontal lobe dysfunction in Parkinson’s disease. The cortical focus of neostriatal outflow.
Brain
 
1986
;
109
:
845
–83.
Tilling K, Sterne JA. Capture‐recapture models including covariate effects.
Am J Epidemiol
 
1999
;
149
:
392
–400.
Twelves D, Perkins KS, Counsell C. Systematic review of incidence studies of Parkinson’s disease.
Mov Disord
 
2003
;
18
:
19
–31.
Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, et al. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity.
Am J Epidemiol
 
2003
;
157
:
1015
–22.
Wang YS, Shi YM, Wu ZY, He YX, Zhang BZ. Parkinson’s disease in China. Coordinational Group of Neuroepidemiology, PLA.
Chin Med J (Engl)
 
1991
;
104
:
960
–4.
Wender M, Pruchnik D, Kowal P, Florczak J, Zalejski M. [Epidemiology of Parkinson disease in the Pozna’n province]. [Polish]
Przegl Epidemiol
 
1989
;
43
:
150
–5.
Woods SP, Troster AI. Prodromal frontal/executive dysfunction predicts incident dementia in Parkinson’s disease.
J Int Neuropsychol Soc
 
2003
;
9
:
17
–24.